Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study

Marcel Simon; Lars Harbaum; Tim Oqueka; Stefan Kluge; Hans Klose

doi:10.1177/1753465816676222

Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study

Standard

Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study. / Simon, Marcel; Harbaum, Lars ; Oqueka, Tim ; Kluge, Stefan ; Klose, Hans.

in: THER ADV RESPIR DIS, Jahrgang 11, Nr. 1, 01.2017, S. 9-19.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Simon, M, Harbaum, L , Oqueka, T , Kluge, S & Klose, H 2017, 'Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study', THER ADV RESPIR DIS, Jg. 11, Nr. 1, S. 9-19. https://doi.org/10.1177/1753465816676222

APA

Simon, M., Harbaum, L., Oqueka, T., Kluge, S., & Klose, H. (2017). Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study. THER ADV RESPIR DIS, 11(1), 9-19. https://doi.org/10.1177/1753465816676222

Vancouver

Simon M, Harbaum L , Oqueka T , Kluge S , Klose H. Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study. THER ADV RESPIR DIS. 2017 Jan;11(1):9-19. https://doi.org/10.1177/1753465816676222

Bibtex

@article{871daa691c694a6791bcf3f02dbd17b3,

title = "Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study",

abstract = "BACKGROUND: Endoscopic lung volume reduction coil (LVRC) treatment is an option for selected patients with severe emphysema. In the advanced stages, emphysema leads to respiratory failure: hypoxemia and eventually chronic hypercapnic respiratory failure. It can be hypothesized that LVRC treatment, a procedure targeting hyperinflation and thereby reducing ventilatory workload, may be especially beneficial in patients with chronic hypercapnic respiratory failure. This study was conducted to gain first insights into the effects and the safety of LVRC treatment in patients with emphysema and chronic hypercapnic respiratory failure.METHODS: A retrospective observational study conducted in the Department of Respiratory Medicine at the University Medical Center Hamburg-Eppendorf, Germany on all patients with chronic hypercapnic respiratory failure in whom bilateral LVRC treatment was performed between 1 April 2012 and 30 September 2015.RESULTS: During the study period, bilateral LVRC treatment was performed in 10 patients with chronic hypercapnic respiratory failure. Compared with baseline, bilateral LVRC treatment led to a significant increase in mean forced expiratory volume in one second (FEV1) from 0.5 ± 0.1 l to 0.6 ± 0.2 l (p = 0.004), a decrease in residual volume (RV) from 6.1 ± 0.9 l to 5.6 ± 1.1 l (p = 0.02) and a reduction in partial pressure of carbon dioxide in arterial blood (PaCO2) from 53 ± 5 mmHg to 48 ± 4 mmHg (p = 0.03). One case of hemoptysis requiring readmission to hospital was the only severe adverse event.CONCLUSIONS: LVRC treatment was safe and effective in patients with nonsevere chronic hypercapnic respiratory failure. It led not only to an improvement in lung function but also to a significant decrease in PaCO2.",

author = "Marcel Simon and Lars Harbaum and Tim Oqueka and Stefan Kluge and Hans Klose",

note = "{\textcopyright} The Author(s), 2016.",

year = "2017",

month = jan,

doi = "10.1177/1753465816676222",

language = "English",

volume = "11",

pages = "9--19",

journal = "THER ADV RESPIR DIS",

issn = "1753-4658",

publisher = "SAGE Publications",

number = "1",

}

RIS

TY - JOUR

T1 - Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study

AU - Simon, Marcel

AU - Harbaum, Lars

AU - Oqueka, Tim

AU - Kluge, Stefan

AU - Klose, Hans

PY - 2017/1

Y1 - 2017/1

N2 - BACKGROUND: Endoscopic lung volume reduction coil (LVRC) treatment is an option for selected patients with severe emphysema. In the advanced stages, emphysema leads to respiratory failure: hypoxemia and eventually chronic hypercapnic respiratory failure. It can be hypothesized that LVRC treatment, a procedure targeting hyperinflation and thereby reducing ventilatory workload, may be especially beneficial in patients with chronic hypercapnic respiratory failure. This study was conducted to gain first insights into the effects and the safety of LVRC treatment in patients with emphysema and chronic hypercapnic respiratory failure.METHODS: A retrospective observational study conducted in the Department of Respiratory Medicine at the University Medical Center Hamburg-Eppendorf, Germany on all patients with chronic hypercapnic respiratory failure in whom bilateral LVRC treatment was performed between 1 April 2012 and 30 September 2015.RESULTS: During the study period, bilateral LVRC treatment was performed in 10 patients with chronic hypercapnic respiratory failure. Compared with baseline, bilateral LVRC treatment led to a significant increase in mean forced expiratory volume in one second (FEV1) from 0.5 ± 0.1 l to 0.6 ± 0.2 l (p = 0.004), a decrease in residual volume (RV) from 6.1 ± 0.9 l to 5.6 ± 1.1 l (p = 0.02) and a reduction in partial pressure of carbon dioxide in arterial blood (PaCO2) from 53 ± 5 mmHg to 48 ± 4 mmHg (p = 0.03). One case of hemoptysis requiring readmission to hospital was the only severe adverse event.CONCLUSIONS: LVRC treatment was safe and effective in patients with nonsevere chronic hypercapnic respiratory failure. It led not only to an improvement in lung function but also to a significant decrease in PaCO2.

AB - BACKGROUND: Endoscopic lung volume reduction coil (LVRC) treatment is an option for selected patients with severe emphysema. In the advanced stages, emphysema leads to respiratory failure: hypoxemia and eventually chronic hypercapnic respiratory failure. It can be hypothesized that LVRC treatment, a procedure targeting hyperinflation and thereby reducing ventilatory workload, may be especially beneficial in patients with chronic hypercapnic respiratory failure. This study was conducted to gain first insights into the effects and the safety of LVRC treatment in patients with emphysema and chronic hypercapnic respiratory failure.METHODS: A retrospective observational study conducted in the Department of Respiratory Medicine at the University Medical Center Hamburg-Eppendorf, Germany on all patients with chronic hypercapnic respiratory failure in whom bilateral LVRC treatment was performed between 1 April 2012 and 30 September 2015.RESULTS: During the study period, bilateral LVRC treatment was performed in 10 patients with chronic hypercapnic respiratory failure. Compared with baseline, bilateral LVRC treatment led to a significant increase in mean forced expiratory volume in one second (FEV1) from 0.5 ± 0.1 l to 0.6 ± 0.2 l (p = 0.004), a decrease in residual volume (RV) from 6.1 ± 0.9 l to 5.6 ± 1.1 l (p = 0.02) and a reduction in partial pressure of carbon dioxide in arterial blood (PaCO2) from 53 ± 5 mmHg to 48 ± 4 mmHg (p = 0.03). One case of hemoptysis requiring readmission to hospital was the only severe adverse event.CONCLUSIONS: LVRC treatment was safe and effective in patients with nonsevere chronic hypercapnic respiratory failure. It led not only to an improvement in lung function but also to a significant decrease in PaCO2.

U2 - 10.1177/1753465816676222

DO - 10.1177/1753465816676222

M3 - SCORING: Journal article

C2 - 27784816

VL - 11

SP - 9

EP - 19

JO - THER ADV RESPIR DIS

JF - THER ADV RESPIR DIS

SN - 1753-4658

IS - 1

ER -